Ocular relapse in acute myeloid leukemia (M4) with normal bone marrow.
A patient with the rare occurrence of ocular relapse of acute myeloid leukemia (AML) M4 while the bone marrow was normal is reported in this paper. A 47-year-old woman with AML was treated with chemotherapy and went successfully into remission. Four months later, she presented with pain, redness, and a mass over the left eye. The ocular relapse involved the subconjunctival space and anterior chamber of the left eye and, presumably, the left lacrimal gland. There were also multiple subcutaneous nodules on both of her forearms. Incisional biopsy from the subconjunctival lesion was performed. Histopathological examination of the specimen showed diffuse blast cell infiltration. Her bone marrow was still in remission. Although exceedingly rare, ocular extramedullary relapse in AML M4 heralds bone marrow recurrence and, despite intensive chemotherapy, the prognosis is dismal.
Kiratli
Hayyam
H
Department of Ophthalmology, Ocular Oncology Service, Hacettepe University School of Medicine, Hacettepe Hastanesi Goz ABD, Sihhiye, Ankara, Turkey. hkiratli@hacettepe.edu.tr
Demiroğlu
Haluk
H
Emeç
Serkan
S
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology*; D005123:Eye / Q000473:pathology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007937:Leukapheresis; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000473:pathology* / Q000628:therapy; D017254:Leukemic Infiltration / Q000209:etiology; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D023981:Sarcoma, Myeloid / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents